Type 1 Diabetes Genetics: Understanding HLA Genes and Autoimmune Risk

Type 1 diabetes (T1D) represents one of the most common autoimmune disorders of childhood, affecting approximately 1.6 million Americans with incidence rates increasing globally at approximately 3% annually (Maahs et al., 2010). Unlike Type 2 diabetes, which involves insulin resistance and has strong environmental and lifestyle components, Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency. The genetic architecture of T1D is among the best understood of any autoimmune condition, with the human leukocyte antigen (HLA) region contributing approximately 50% of the genetic risk (Noble & Valdes, 2011). Understanding these genetic factors provides critical insights into disease prediction, family risk assessment, and the underlying mechanisms of autoimmune dysregulation.

The Central Role of HLA Genes in Type 1 Diabetes

The human leukocyte antigen (HLA) complex, located on chromosome 6p21.3, encodes the major histocompatibility complex (MHC) proteins responsible for antigen presentation to T cells. This region represents the most gene-dense area of the human genome and exhibits extraordinary polymorphism, with thousands of allelic variants that influence immune recognition and response (Trowsdale & Knight, 2013). In Type 1 diabetes, specific HLA class II haplotypes dramatically alter disease risk, with some combinations increasing susceptibility more than 10-fold while others confer strong protection.

HLA Class II: The Primary Determinants of T1D Risk

HLA class II molecules, expressed on antigen-presenting cells including dendritic cells, macrophages, and B lymphocytes, present processed peptide antigens to CD4+ T helper cells. The HLA-DR and HLA-DQ loci within the class II region demonstrate the strongest associations with Type 1 diabetes susceptibility (Erlich et al., 2008). These molecules consist of alpha and beta chains encoded by DQA1/DQB1 and DRA/DRB1 genes, respectively, with the peptide-binding groove formed at the interface between chains.

The HLA-DQ8 haplotype, encoded by DQA103:01-DQB103:02, represents the highest-risk genotype for Type 1 diabetes in most populations, conferring an odds ratio of approximately 10-15 for heterozygous carriers and substantially higher risk for homozygous individuals (Rewers & Ludvigsson, 2016). Similarly, the HLA-DQ2 haplotype (DQA105:01-DQB102:01) significantly increases T1D susceptibility, though typically to a lesser degree than DQ8. These risk haplotypes share a common structural feature: both encode DQ beta chains with a specific amino acid at position 57—alanine in the case of DQB103:02 and serine in DQB102:01—rather than the aspartic acid found in protective alleles (Todd et al., 1987). This amino acid substitution alters the peptide-binding pocket, potentially facilitating presentation of beta-cell-derived autoantigens to autoreactive T cells.

The HLA-DR4 haplotype, particularly DRB1*04:01, *04:04, and 04:05, demonstrates strong linkage disequilibrium with DQ8 and independently contributes to T1D risk. DR3 (DRB103:01), typically inherited with DQ2, represents another major risk haplotype. Individuals who inherit both DR3-DQ2 and DR4-DQ8 face the highest genetic risk, with approximately 1 in 15 developing Type 1 diabetes compared to the general population risk of 1 in 300 (Gillespie et al., 2004). This synergistic risk enhancement suggests complementary roles in immune dysregulation, potentially involving distinct antigen presentation pathways or thymic selection processes.

Protective HLA Haplotypes

While much attention focuses on risk-conferring variants, certain HLA haplotypes provide remarkably robust protection against Type 1 diabetes development. The DQA101:02-DQB106:02 haplotype, often inherited with DRB1*15:01, reduces T1D risk by approximately 90% even in individuals with high-risk family backgrounds (Erlich et al., 2008). This protective effect appears dominant, as the presence of a single protective haplotype substantially mitigates risk from susceptibility alleles on the opposite chromosome.

The molecular basis of this protection involves the aspartic acid residue at position 57 of the DQB1 chain, which creates a salt bridge within the peptide-binding groove that alters antigen binding and presentation (Suri et al., 2005). Additionally, protective haplotypes may facilitate more efficient negative selection of autoreactive T cells during thymic development or promote regulatory T cell populations that suppress autoimmune responses. Understanding these protective mechanisms offers potential therapeutic avenues for preventing or arresting Type 1 diabetes progression.

HLA Class I Associations and Beta Cell Targeting

Beyond the well-established class II associations, HLA class I molecules play critical roles in Type 1 diabetes pathogenesis through their presentation of peptide antigens to CD8+ cytotoxic T cells. These cytotoxic lymphocytes represent the primary effectors of beta cell destruction, recognizing and killing insulin-producing cells that display autoantigenic peptides on HLA-A, HLA-B, or HLA-C molecules (Skowera et al., 2008).

Genome-wide association studies have identified specific HLA class I alleles that modify T1D risk. The HLA-A24 allele increases susceptibility independently of class II effects, potentially through altered presentation of preproinsulin peptides or other beta cell antigens (Howson et al., 2009). Conversely, HLA-B39 and certain HLA-C variants demonstrate protective associations, suggesting that class I antigen presentation efficiency influences the activation and expansion of autoreactive cytotoxic T cell populations.

The interaction between class I and class II-mediated immunity highlights the complexity of HLA contributions to Type 1 diabetes. Optimal autoimmune destruction of beta cells likely requires coordinated CD4+ T helper cell activation—facilitated by disease-associated class II molecules—and CD8+ cytotoxic T cell effector function directed by specific class I alleles. This multi-step genetic susceptibility explains why HLA effects on T1D risk are both substantial and complex, involving multiple loci and epistatic interactions.

Non-HLA Genetic Factors in Type 1 Diabetes

While the HLA region contributes approximately 50% of the genetic risk for Type 1 diabetes, genome-wide association studies have identified more than 60 additional susceptibility loci scattered throughout the genome (Onengut-Gumuscu et al., 2015). These non-HLA genetic factors individually confer modest risk increases—typically odds ratios of 1.1 to 1.5—but collectively account for substantial heritability and provide insights into disease mechanisms beyond antigen presentation.

The Insulin Gene (INS) Variable Number Tandem Repeat

The insulin gene (INS) on chromosome 11p15.5 contains a variable number tandem repeat (VNTR) polymorphism upstream of the transcription start site that significantly influences Type 1 diabetes risk. This minisatellite region consists of repeating sequences ranging from 26 to 63+ copies, categorized into three classes based on length (Bennett et al., 1995). Class I alleles (26-63 repeats) associate with increased T1D risk, while class III alleles (140-210 repeats) confer protection.

The mechanism underlying this association involves thymic insulin expression, which plays a critical role in immune tolerance development. The protective class III VNTR promotes higher insulin expression in thymic epithelial cells, enhancing negative selection of insulin-reactive T cells during immune development (Pugliese et al., 1997). Conversely, class I alleles reduce thymic insulin expression, potentially allowing autoreactive T cells to escape central tolerance mechanisms and subsequently target pancreatic beta cells. This genetic effect demonstrates how tissue-specific gene regulation influences autoimmune susceptibility independent of the HLA-mediated antigen presentation pathway.

PTPN22 and T Cell Receptor Signaling

The protein tyrosine phosphatase non-receptor type 22 gene (PTPN22) encodes lymphoid tyrosine phosphatase (LYP), a critical negative regulator of T cell receptor signaling. A single nucleotide polymorphism in PTPN22 (rs2476601, Arg620Trp) creates a gain-of-function variant that enhances inhibitory signaling and reduces T cell activation thresholds (Bottini et al., 2004).

The Trp620 allele increases Type 1 diabetes risk with an odds ratio of approximately 1.8-2.0 and shows association with multiple other autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, and autoimmune thyroid disease. This pleiotropic autoimmune association suggests that PTPN22 variants create a generalized immune dysregulation that predisposes to multiple autoimmune phenotypes rather than specifically targeting beta cells. The mechanism involves altered thymic selection, peripheral T cell activation thresholds, and potentially impaired regulatory T cell function.

IL2RA and Immune Regulation

The interleukin-2 receptor alpha chain gene (IL2RA), also known as CD25, encodes a component of the high-affinity IL-2 receptor essential for regulatory T cell development and function. Multiple variants within IL2RA associate with Type 1 diabetes risk, affecting both disease susceptibility and progression from autoimmunity to clinical diabetes (Lowe et al., 2007).

IL-2 signaling promotes the survival and function of forkhead box P3 (FOXP3)-positive regulatory T cells, which suppress autoreactive T cell responses. Reduced IL2RA expression or function impairs this regulatory mechanism, potentially allowing unchecked expansion of beta cell-reactive effector T cells. The IL2RA association exemplifies how genetic variants affecting immune regulation—not just antigen recognition—contribute to autoimmune diabetes pathogenesis.

Additional Susceptibility Loci

Other notable non-HLA genes associated with Type 1 diabetes include:

• IFIH1: Interferon-induced helicase C domain-containing protein 1, involved in viral RNA recognition and innate immune response (Smyth et al., 2006)
• CTLA4: Cytotoxic T-lymphocyte-associated protein 4, a negative regulator of T cell activation
• IKZF4: IKAROS family zinc finger 4, involved in immune cell development
• CLEC16A: C-type lectin domain family 16 member A, with functions in autophagy and immune regulation
• SH2B3: SH2B adaptor protein 3, involved in cytokine signaling and hematopoiesis

Each of these loci implicates specific biological pathways—viral response, T cell regulation, autophagy, cytokine signaling—in Type 1 diabetes development, revealing the multifactorial nature of autoimmune dysregulation.

Polygenic Risk Scoring for Type 1 Diabetes

Polygenic risk scores (PRS) aggregate the effects of thousands of genetic variants across the genome to quantify overall genetic susceptibility to complex diseases. In Type 1 diabetes, polygenic risk scoring incorporates HLA genotypes, non-HLA susceptibility variants, and protective alleles to generate individualized risk estimates that substantially exceed the predictive power of any single genetic marker (Oram et al., 2015).

Current T1D polygenic risk scores demonstrate clinically meaningful discriminative ability, identifying individuals in the top decile of genetic risk who have 10- to 20-fold increased disease probability compared to the population average. For first-degree relatives of Type 1 diabetes patients—who already face elevated baseline risk of 5-10%—polygenic risk scoring can stratify individuals into categories ranging from near-population risk to risks exceeding 50% (Sharp et al., 2019).

The clinical utility of polygenic risk scoring in Type 1 diabetes extends beyond prediction to screening and prevention. Genetic risk stratification enables targeted monitoring for islet autoantibody development in high-risk children, facilitating early detection of pre-symptomatic autoimmunity. Research programs such as TEDDY (The Environmental Determinants of Diabetes in the Young) utilize genetic screening to identify high-risk infants for longitudinal follow-up, enabling detailed characterization of the preclinical disease process and testing of preventive interventions (Hagopian et al., 2011).

Gene-Environment Interactions in Type 1 Diabetes

While genetic factors establish susceptibility, environmental triggers appear necessary to initiate the autoimmune process in most cases of Type 1 diabetes. Concordance rates among monozygotic twins—who share identical genetic backgrounds—range from 30-50%, indicating substantial environmental contribution to disease development (Hyttinen et al., 2003). Understanding gene-environment interactions is essential for comprehensive risk assessment and preventive strategies.

Viral Triggers and Genetic Susceptibility

Viral infections, particularly enteroviruses, have long been implicated in Type 1 diabetes initiation. The IFIH1 gene, which encodes a cytoplasmic sensor of viral RNA, provides compelling genetic evidence for this association. A protective variant in IFIH1 (rs1990760, Ala946Thr) reduces Type 1 diabetes risk by approximately 50% and simultaneously decreases inflammatory responses to viral infection (Nejentsev et al., 2009). This genetic-environmental interaction suggests that viral infection triggers autoimmune beta cell destruction through pathways involving innate immune recognition, with genetic variants in these pathways modulating disease probability.

The Hygiene Hypothesis and Microbiome Interactions

The hygiene hypothesis posits that reduced early-life microbial exposure—associated with modern sanitation, antibiotic use, and birthing practices—alters immune development and increases autoimmune disease risk. Genetic variants affecting gut barrier function, immune recognition of microbial products, and inflammatory responses likely influence individual susceptibility to these environmental changes (Knip & Siljander, 2016).

The rapidly evolving understanding of the gut microbiome's role in immune regulation suggests complex interactions between host genetics, microbial colonization patterns, and Type 1 diabetes risk. Specific HLA haplotypes may influence microbiome composition through effects on antigen presentation and immune selection, creating feedback loops between genetic susceptibility and environmental microbial exposures.

Clinical Implications and Genetic Testing

Genetic testing for Type 1 diabetes risk has transitioned from research applications to clinical utility, particularly for family screening and risk stratification. Commercial genetic testing services can now assess HLA haplotypes, non-HLA susceptibility variants, and polygenic risk scores to provide individualized risk estimates.

Family Screening Applications

For families with an existing Type 1 diabetes proband, genetic testing of siblings enables risk stratification that guides clinical surveillance. High-risk siblings—those carrying DR3-DQ2/DR4-DQ8 genotypes or elevated polygenic risk scores—benefit from regular monitoring for islet autoantibodies, allowing detection of pre-symptomatic disease when preventive interventions might be effective (Insel et al., 2015).

The clinical value of this approach was demonstrated by the Diabetes Prevention Trial–Type 1, which showed that oral insulin administration could delay diabetes onset in high-risk individuals with specific autoantibody profiles. Genetic risk stratification helps identify candidates for such prevention trials and future approved interventions.

Population Screening Considerations

Population-wide genetic screening for Type 1 diabetes risk remains controversial due to the low absolute risk in the general population and limited preventive options for identified high-risk individuals. However, as polygenic risk scores improve and effective prevention strategies emerge, genetic screening may become standard practice, analogous to newborn screening for other treatable conditions.

Several research programs have demonstrated the feasibility of population-based genetic screening. The Fr1da study in Bavaria, Germany, genetically screened more than 90,000 children for T1D risk, identifying high-risk individuals for autoantibody monitoring and early insulin therapy initiation (Ziegler et al., 2015). Such programs provide proof-of-concept for scalable genetic screening while generating critical data on the natural history of genetically-defined T1D risk.

Conclusion

The genetics of Type 1 diabetes exemplify the complex interplay between immune recognition, tolerance mechanisms, and environmental triggers that characterizes autoimmune disease. The HLA region's dominant contribution—mediated through antigen presentation to autoreactive T cells—combines with dozens of non-HLA loci affecting immune regulation, thymic selection, and viral responses to create individualized susceptibility profiles. Modern polygenic risk scoring captures this complexity, enabling risk stratification with clinically meaningful precision.

As understanding of T1D genetics continues to evolve, the integration of genetic risk assessment into clinical practice promises earlier detection, targeted monitoring, and ultimately preventive interventions for this chronic autoimmune condition. For individuals with family histories of Type 1 diabetes or other autoimmune conditions, genetic testing offers valuable insights into personal risk and opportunities for proactive health management.

Explore Your Own Genetics

Curious about your genetic risk for Type 1 diabetes and other autoimmune conditions? Genome Insight analyzes your DNA data to provide personalized insights into HLA haplotypes, autoimmune susceptibility, and over 500 health traits and conditions—completely free.

Upload your DNA data →

Related Reading

• Is Lupus Genetic? SLE DNA and Hereditary Risk – Understanding systemic lupus erythematosus genetics
• Celiac Disease Genetic Testing: HLA-DQ2 and DQ8 – How HLA genes influence celiac disease risk
• Is Multiple Sclerosis Genetic? DNA Testing Insights – Autoimmune neurological disease genetics
• Polygenic Risk Scores Explained – How genetic risk scoring works for complex diseases
• What to Do With Your 23andMe Raw Data – Maximizing value from your genetic data
• MTHFR Gene Mutation: What Your DNA Reveals – Understanding gene variant testing

References

Bennett, S. T., Lucassen, A. M., Gough, S. C., Powell, E. E., Undlien, D. E., Pritchard, L. E., Merriman, M. E., Kawaguchi, Y., Dronsfield, M. J., & Pociot, F. (1995). Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genetics, 9(3), 284–292. https://doi.org/10.1038/ng0395-284

Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., MacMurray, J., Meloni, G. F., Lucarelli, P., Pellecchia, M., Eisenlohr, L., Comings, D., & Mustelin, T. (2004). A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics, 36(4), 337–338. https://doi.org/10.1038/ng1323

Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., Mychaleckyj, J. C., Todd, J. A., Bonella, P., Fear, A. L., Lavant, E., Louey, A., & Moonsamy, P. (2008). HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: Analysis of the type 1 diabetes genetics consortium families. Diabetes, 57(4), 1084–1092. https://doi.org/10.2337/db07-1331

Gillespie, K. M., Bain, S. C., Barnett, A. H., Bingley, P. J., Christie, M. R., Gill, G. V., & Gale, E. A. (2004). The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. The Lancet, 364(9446), 1699–1700. https://doi.org/10.1016/S0140-6736(04)17357-1

Hagopian, W. A., Lernmark, Å., Rewers, M. J., Simell, O. G., She, J. X., Ziegler, S. F., & Krischer, J. P. (2011). TEDDY—The environmental determinants of diabetes in the young: An observational clinical trial. Annals of the New York Academy of Sciences, 1079(1), 320–326. https://doi.org/10.1196/annals.1375.049

Howson, J. M., Walker, N. M., Clayton, D., & Todd, J. A. (2009). Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes, 61(8), 2056–2064. https://doi.org/10.2337/db09-0362

Hyttinen, V., Kaprio, J., Kinnunen, L., Koskenvuo, M., & Tuomilehto, J. (2003). Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs. Diabetes, 52(4), 1052–1055. https://doi.org/10.2337/diabetes.52.4.1052

Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., Ratner, R. E., Rewers, M. J., Schatz, D. A., Skyler, J. S., Sosenko, J. M., & Ziegler, A. G. (2015). Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 38(10), 1964–1974. https://doi.org/10.2337/dc15-1419

Knip, M., & Siljander, H. (2016). The role of the intestinal microbiota in type 1 diabetes mellitus. Nature Reviews Endocrinology, 12(3), 154–167. https://doi.org/10.1038/nrendo.2015.218

Lowe, C. E., Cooper, J. D., Brusko, T., Walker, N. M., Smyth, D. J., Bailey, R., Bourget, K., Plagnol, V., Field, S., Atkinson, M., Clayton, D. G., Wicker, L. S., & Todd, J. A. (2007). Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genetics, 39(9), 1074–1082. https://doi.org/10.1038/ng2102

Maahs, D. M., West, N. A., Lawrence, J. M., & Mayer-Davis, E. J. (2010). Epidemiology of type 1 diabetes. Endocrinology and Metabolism Clinics of North America, 39(3), 481–497. https://doi.org/10.1016/j.ecl.2010.05.011

Nejentsev, S., Walker, N., Riches, D., Egholm, M., & Todd, J. A. (2009). Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science, 324(5925), 387–389. https://doi.org/10.1126/science.1167728

Noble, J. A., & Valdes, A. M. (2011). Genetics of the HLA region in the prediction of type 1 diabetes. Current Diabetes Reports, 11(6), 533–542. https://doi.org/10.1007/s11892-011-0223-x

Onengut-Gumuscu, S., Chen, W. M., Burren, O., Cooper, N. J., Quinlan, A. R., Mychaleckyj, J. C., Farber, E., Barnett, R., Smyth, D. J., Achmadi, J., D Montgomery, A., Kretowski, A., & Todd, J. A. (2015). Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nature Genetics, 47(4), 381–386. https://doi.org/10.1038/ng.3245

Oram, R. A., Patel, K., Hill, A., Shields, B., McDonald, T. J., Jones, A., Hattersley, A. T., & Weedon, M. N. (2015). A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care, 38(2), 337–344. https://doi.org/10.2337/dc14-1111

Pugliese, A., Zeller, M., Fernandez, A., Zalcberg, L. J., Bartlett, R. J., Ricordi, C., Pietropaolo, M., Eisenbarth, G. S., Bennett, S. T., & Patel, D. D. (1997). The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nature Genetics, 15(3), 293–297. https://doi.org/10.1038/ng0397-293

Rewers, M., & Ludvigsson, J. (2016). Environmental risk factors for type 1 diabetes. The Lancet, 387(10035), 2340–2348. https://doi.org/10.1016/S0140-6736(16)30507-4

Sharp, S. A., Rich, S. S., Wood, A. R., Jones, S. E., Beaumont, R. N., Harrison, J. W., Schneider, D. A., Locke, A. E., Li, M., & Grant, S. F. (2019). Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care, 42(11), 2001–2008. https://doi.org/10.2337/dc19-0882

Skowera, A., Ellis, R. J., Varela-Calviño, R., Arif, S., Huang, G. C., Van-Krinks, C., Zaremba, A., Rackham, C., Allen, J. S., Tree, T. I., Zhao, M., Dayan, C. M., Sewell, A. K., Unger, W., Drijfhout, J. W., Ossendorp, F., Roep, B. O., & Peakman, M. (2008). CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. The Journal of Clinical Investigation, 118(10), 3390–3402. https://doi.org/10.1172/JCI35458

Smyth, D. J., Cooper, J. D., Bailey, R., Field, S., Burren, O., Smink, L. J., Guja, C., Ionescu-Tîrgoviște, C., Widmer, B., Dunger, D. B., Savage, D. A., Walker, N. M., Clayton, D. G., & Todd, J. A. (2006). A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nature Genetics, 38(6), 617–619. https://doi.org/10.1038/ng1800

Todd, J. A., Bell, J. I., & McDevitt, H. O. (1987). HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature, 329(6140), 599–604. https://doi.org/10.1038/329599a0

Trowsdale, J., & Knight, J. C. (2013). Major histocompatibility complex genomics and human disease. Annual Review of Genomics and Human Genetics, 14, 301–323. https://doi.org/10.1146/annurev-genom-091212-153455

Ziegler, A. G., Kick, K., Bonifacio, E., Puff, R., Peplow, C., & Beyerlein, A. (2015). Genetic contribution to the development of type 1 diabetes. Hormone Research in Paediatrics, 83(3), 143–148. https://doi.org/10.1159/000369127